Across TCGA pan-cancer cohorts, MYO18A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYO18A data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MYO18A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO18A expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

GBM, HNSC, and LSCC are the cancer types where MYO18A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.205	0.557	.002	12	view →
HNSC	OS	Median	IV	0.925	0.761	.010	10	view →
LSCC	DFS	Quartile	II,III,IV	0.586	0.945	.009	9	view →
CCRCC	DFS	Median	III,IV	0.818	0.244	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MYO18A tumor-vs-normal RNA expression · all MYO18A data types